Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Chief Scientific Officer | July 15, 2022 | July 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date July 15, 2022 · Filed July 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,100 |
Ending reported balance
After 2022-07-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-15 · Exercise / conversion · Acquired 46,034 · Balance 141,134 Row 2 · 2022-07-15 · Sale · Disposed 46,034 · Balance 95,100 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2028-03-25 | Direct | 8,755 |
Reported balance
After 2022-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-15 · Exercise / conversion · Disposed 46,034 · Balance 8,755 F2: Immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: Immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2022 Filed Jul 19, 2022 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 46,034 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-042573 · doc4.xml · derivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,755 Underlying: Common Stock · 46,034 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 46,034 | $30.00 | $1,381,020.00 |
DisclosureSEC source: 0001209191-22-042573 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,100 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 46,034 | $0.30 | $13,810.20 |
DisclosureSEC source: 0001209191-22-042573 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,916 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-042253 · doc4.xml · derivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,789 Underlying: Common Stock · 1,916 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,916 | $30.00 | $57,480.00 |
DisclosureSEC source: 0001209191-22-042253 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,100 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 1,916 | $0.30 | $574.80 |
DisclosureSEC source: 0001209191-22-042253 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 18:57 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,400 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-036800 · doc4.xml · derivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,705 Underlying: Common Stock · 9,400 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 18:57 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 9,400 | $0.30 | $2,820.00 |
DisclosureSEC source: 0001209191-22-036800 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-028889 · doc4.xml · derivative · entry 7 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,105 Underlying: Common Stock · 5,300 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 16 | $45.45 | $727.20 |
DisclosureSEC source: 0001209191-22-028889 · doc4.xml · nonDerivative · entry 6 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.31 to $45.46 inclusive. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 223 | $44.23 | $9,863.29 |
DisclosureSEC source: 0001209191-22-028889 · doc4.xml · nonDerivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.075 to $44.43 inclusive. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 719 | $43.32 | $31,147.08 |
DisclosureSEC source: 0001209191-22-028889 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,939 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $43.62 inclusive. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 944 | $42.49 | $40,110.56 |
DisclosureSEC source: 0001209191-22-028889 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,658 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.915 to $42.90 inclusive. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,398 | $41.26 | $140,201.48 |
DisclosureSEC source: 0001209191-22-028889 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,602 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.915 to $41.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6). Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 5,300 | $0.30 | $1,590.00 |
DisclosureSEC source: 0001209191-22-028889 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-024290 · doc4.xml · derivative · entry 6 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,405 Underlying: Common Stock · 5,300 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 559 | $64.15 | $35,859.85 |
DisclosureSEC source: 0001209191-22-024290 · doc4.xml · nonDerivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.00 to $64.49 inclusive. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,315 | $63.50 | $147,002.50 |
DisclosureSEC source: 0001209191-22-024290 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,259 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.975 to $63.865 inclusive. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,009 | $62.32 | $62,880.88 |
DisclosureSEC source: 0001209191-22-024290 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,574 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.975 to $62.97 inclusive. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,417 | $61.37 | $86,961.29 |
DisclosureSEC source: 0001209191-22-024290 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,583 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.97 to $61.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5). Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 5,300 | $0.30 | $1,590.00 |
DisclosureSEC source: 0001209191-22-024290 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:49 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionof Shares Employee Stock Option (right to buy) · Derivative | 7,950 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-023494 · doc4.xml · derivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,705 Underlying: Common Stock · 7,950 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:49 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 7,950 | $60.00 | $477,000.00 |
DisclosureSEC source: 0001209191-22-023494 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:49 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 7,950 | $0.30 | $2,385.00 |
DisclosureSEC source: 0001209191-22-023494 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,650 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-018836 · doc4.xml · derivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,655 Underlying: Common Stock · 2,650 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 875 | $54.54 | $47,722.50 |
DisclosureSEC source: 0001209191-22-018836 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.225 to $55.13 inclusive. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 713 | $53.36 | $38,045.68 |
DisclosureSEC source: 0001209191-22-018836 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,575 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.06 to $53.83 inclusive. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,062 | $52.43 | $55,680.66 |
DisclosureSEC source: 0001209191-22-018836 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.03 to $53.025 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 2,650 | $0.30 | $795.00 |
DisclosureSEC source: 0001209191-22-018836 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:26 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,650 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-009792 · doc4.xml · derivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,305 Underlying: Common Stock · 2,650 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:26 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 199 | $53.10 | $10,566.90 |
DisclosureSEC source: 0001209191-22-009792 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.06 to $53.17 inclusive. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:26 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,378 | $52.35 | $72,138.30 |
DisclosureSEC source: 0001209191-22-009792 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,899 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.99 to $52.805 inclusive. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:26 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,073 | $51.50 | $55,259.50 |
DisclosureSEC source: 0001209191-22-009792 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.97 to $51.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:26 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 2,650 | $0.30 | $795.00 |
DisclosureSEC source: 0001209191-22-009792 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 16:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $46.30 | $0.00 |
DisclosureSEC source: 0001209191-22-004763 · doc4.xml · derivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,650 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-003198 · doc4.xml · derivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,955 Underlying: Common Stock · 2,650 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,134 | $54.45 | $61,746.30 |
DisclosureSEC source: 0001209191-22-003198 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.075 to $54.85 inclusive. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,196 | $53.56 | $64,057.76 |
DisclosureSEC source: 0001209191-22-003198 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,834 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.035 to $53.98 inclusive. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 320 | $52.01 | $16,643.20 |
DisclosureSEC source: 0001209191-22-003198 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,030 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.695 to $52.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 2,650 | $0.30 | $795.00 |
DisclosureSEC source: 0001209191-22-003198 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 16:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,650 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-002416 · doc4.xml · derivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,605 Underlying: Common Stock · 2,650 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 16:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,650 | $60.00 | $159,000.00 |
DisclosureSEC source: 0001209191-22-002416 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 16:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 2,650 | $0.30 | $795.00 |
DisclosureSEC source: 0001209191-22-002416 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 15, 2021 16:48 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 735 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · derivative · entry 8 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,255 Underlying: Common Stock · 735 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 15, 2021 Filed Dec 15, 2021 16:48 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 735 | $50.00 | $36,750.00 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · nonDerivative · entry 6 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 15, 2021 Filed Dec 15, 2021 16:48 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 735 | $0.30 | $220.50 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · nonDerivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 16:48 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,915 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · derivative · entry 7 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,990 Underlying: Common Stock · 1,915 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 16:48 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 7 | $53.64 | $375.48 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 16:48 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 390 | $52.22 | $20,365.80 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,707 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.06 to $52.86 inclusive. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 16:48 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,518 | $50.11 | $76,066.98 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,097 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.